Morningstar

SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a ...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ABLi will leverage the ability ...
MarketWatch

(PMZN) SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...